Contact Us |
GHDonline is part of the Global Health Delivery Project at Harvard University.
Please see this blog post and attached article on this issue which does not get much attention (as compared to counterfeit medicines). URL: https://www.ibm.com/blogs/research/2018/06/ink-spots-end-counterfeit-diagnost...
Hi AllMany thanks for this. I would just like to point out that the description "counterfeit" is not longer relevant since the WHO updated their definition as "The old “substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC)” terminology surfaced from the lack of a global common understanding, sometimes confusing the phenomenon of substandard and falsified products with the protection of intellectual property rights."Thus we should also be consistent in what we mean by counterfeit diagnostics consistent with this WHO definition.Please see here: http://www.who.int/medicines/regulation/ssffc/definitions/en/best wishesTeri-- Teri ROBERTSDiagnostics Advisor for fever & AMR | MSF Access Campaignoffice: +41 22 849 87 27Skype: teri.roberts | twitter.com/#!/DxTeri
Thanks for this post (and for a great course in Montréal this week)!The issue with falsified diagnostic assays needs to be taken serious. These "assays" not only lead to wrongful clinical decision making, what's worse is that they create a distrust amongst health providers (and probably also patients) in real assays and their results. Something we bumped into when discussing POC tests with health care workers in Mbarara, Uganda:/Reza RastiKarolinska Institutet
Link leads to: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182005